AN2 Therapeutics Inc (ANTX)
1.39
+0.03
(+2.21%)
USD |
NASDAQ |
Dec 26, 14:58
AN2 Therapeutics Free Cash Flow: -61.05M for Sept. 30, 2024
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Biomarin Pharmaceutical Inc | 300.88M |
| Arbutus Biopharma Corp | -71.92M |
| GlycoMimetics Inc | -35.02M |
| FibroGen Inc | -126.23M |
| Cidara Therapeutics Inc | -160.15M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -12.01M |
| Cash from Investing (Quarterly) | 18.72M |
| Cash from Financing (Quarterly) | 0.023M |
| Free Cash Flow Per Share (Quarterly) | -0.4024 |
| Free Cash Flow Yield | -147.4% |